Q-omics provides the consensus-scored MRPL39 profile across patient tissues and cancer cell-line models. MRPL39 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL39 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, MRPL39 protein abundance shows 21,094 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where MRPL39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL39 survival associations across molecular data types. MRPL39 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL39 RNA expression–survival associations across cancer types. High MRPL39 expression shows unfavorable associations in UVM, LUAD, SCLC, LGG and ACC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL39 RNA expression.
This table summarizes MRPL39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL39 shows lower tumor expression in KICH, THCA and PAAD and higher tumor expression in BLCA, UCEC and LUSC. The BLCA box plot shows higher MRPL39 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with MRPL39 in patient tissues and cancer cell lines. In patient samples, MRPL39 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL39 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
